Fate Therapeutics, Inc. (FATE)

Fate Therapeutics' stock price has increased from $1.03 per share on May 8, 2025, to $2.43 as of May 7, 2026. Key events include Q4 2025 earnings report with an EPS of -$0.27, announcement of successful outpatient treatment of autoimmune patients with FT819, preclinical data for FT839 featured at the American Association for Cancer Research Annual Meeting, clinical data from FT819 presented at the Congress of Clinical Rheumatology – East meeting, presentations at the 2026 ASGCT Annual Meeting, and selection of FT819 for the FDA's CMC Development and Readiness Pilot Program. The company is expected to announce its Q1 2026 earnings around May 22, 2026, with projected EPS of -$0.28.

Demand for Fate Therapeutics' products and services is not subject to traditional seasonal fluctuations. Demand is primarily driven by disease prevalence, clinical trial outcomes, unmet medical needs, and the accessibility and efficacy of their therapies.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. They utilize a proprietary iPSC platform to create off-the-shelf NK cell and T-cell product candidates, aiming to overcome limitations of patient- or donor-sourced cell therapies. Their pipeline includes FT819 for B-cell malignancies and SLE, FT522 for relapsed/refractory B-cell lymphoma and autoimmunity, FT836 for advanced solid tumors, FT839 for hematological malignancies and autoimmune diseases, FT825 for advanced solid tumors (in collaboration with Ono Pharmaceutical), and ProHema for hematologic malignancies.

Fate Therapeutics is headquartered in San Diego, California, which serves as its primary operational hub. The company also has a subsidiary in Ottawa, Canada. Clinical trial activities for product candidates like FT819 have expanded across multiple sites in the U.S., U.K., and EU.

Fate Therapeutics has a reputation for scientific excellence, supported by its iPSC product platform and extensive intellectual property portfolio. The company is recognized as a leader in developing first-in-class cellular immunotherapies. Clinical progress with FT819, selection for the FDA's CDRP program, and data presentations at scientific conferences have positively impacted its reputation.

Fate Therapeutics' ownership is predominantly institutional, with 149 institutional owners holding a total of 81,461,201 shares. Major institutional owners include Redmile Group, LLC, BlackRock, Inc., and Vanguard Group Inc. Significant individual or insider owners include Redmile Group LLC, Amir Nashat, and Polaris Venture Management Co V LLC.